15 completed. 15 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 15 | Completed 15 |
Follow Bronchiectasis: new trials by email Literature Review of Bronchiectasis trials Research Report on Bronchiectasis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Randomised Open Label Trial of Hypertonic Saline and Carbocisteine in Bronchiectasis (CLEAR) Hypertonic saline, Carbocysteine 750 MG - Bronchiectasis | Phase 3 | Completed | Belfast Health and Social Care Trust | 288 | 2018-06-27 | 2025-05-02 |
| Efficacy of Roflumilast on Exacerbations in Patients With Non-cystic Fibrosis Bronchiectasis Roflumilast, Placebo - Exacerbation Copd, Bronchiectasis | Phase 3 | Completed | Prince of Songkla University | 40 | 2015-01-01 | 2019-10-10 |
| Ciprofloxacin Dry Powder for Inhalation (DPI) in Non-cystic Fibrosis Bronchiectasis (Non-CF BE) Ciprofloxacin (BAYQ3939) dry powder for inhalation, Placebo - Bronchiectasis | Phase 3 | Completed | Bayer | 521 | 2014-04-30 | 2017-10-02 |
| Phase 3 Study With Ciprofloxacin Dispersion for Inhalation in Non-CF Bronchiectasis (ORBIT-3) Ciprofloxacin dispersion for inhalation, Placebo - Non Cystic Fibrosis Bronchiectasis | Phase 3 | Completed | Aradigm Corporation | 278 | 2014-03-31 | 2021-03-26 |
| Ciprofloxacin Dry Powder for Inhalation in Non-cystic Fibrosis Bronchiectasis (Non-CF BE) Ciprofloxacin DPI (BAYQ3939), Placebo - Bronchiectasis | Phase 3 | Completed | Bayer | 416 | 2013-05-02 | 2018-01-24 |
| Prevention of Bronchiectasis in Infants With Cystic Fibrosis Azithromycin, Placebo control - Cystic Fibrosis, Bronchiectasis | Phase 3 | Completed | The University of Queensland | 130 | 2012-04-01 | 2021-09-16 |
| Safety and Effectiveness of AZLI (an Inhaled Antibiotic) in Adults With Non-Cystic Fibrosis Bronchiectasis AZLI, Placebo - Bronchiectasis | Phase 3 | Completed | Gilead Sciences | 266 | 2011-04-01 | 2014-04-16 |
| Safety and Effectiveness of AZLI (an Inhaled Antibiotic) in Adults With Non-Cystic Fibrosis Bronchiectasis AZLI, Placebo - Bronchiectasis | Phase 3 | Completed | Gilead Sciences | 274 | 2011-04-01 | 2014-04-16 |
| Effects of Roxithromycin on Quality of Life and Physiological Outcomes in Bronchiectasis Roxithromycin 300 MG, Placebo - Quality of Life, Respiratory Function Tests | Phase 3 | Completed | Prince of Songkla University | 40 | 2011-03-01 | 2019-10-14 |
| Inhaled Mannitol as a Mucoactive Therapy for Bronchiectasis Inhaled mannitol, Matched control - Bronchiectasis | Phase 3 | Completed | Syntara | 485 | 2009-11-01 | 2016-04-29 |
| Bronchiectasis and Long Term Azithromycin Treatment Azithromycin, Placebo - Bronchiectasis, Inflammation | Phase 3 | Completed | W.G.Boersma | 72 | 2008-04-01 | 2020-05-28 |
| The Long Term Effect of Inhaled Hypertonic Saline (6%) in Patients With Non Cystic Fibrosis Bronchiectasis Hypertonic saline 6% - - Bronchiectasis | Phase 3 | Completed | The Alfred | 40 | 2007-12-01 | 2011-06-23 |
| Therapeutic Confirmatory Clinical Trial to Evaluate the Safety and Efficacy of AG1321001 in Chronic Cougher AG1321001(drug) - Cough | Phase 3 | Completed | Ahn-Gook Pharmaceuticals Co.,Ltd | 396 | 2006-03-01 | 2009-07-02 |
| Safety and Efficacy of Bronchitol in Bronchiectasis Mannitol, placebo - Bronchiectasis | Phase 3 | Completed | Syntara | 354 | 2006-03-01 | 2008-08-29 |
| EZ-2053 in the Prophylaxis of Acute Pulmonary Allograft Rejection Placebo, EZ-2053, EZ-2053 5mg/kg - Chronic Obstructive Pulmonary, Idiopathic Pulmonary Fibrosis | Phase 3 | Completed | Neovii Biotech | 223 | 2005-01-01 | 2012-06-11 |
Cystic Fibrosis (2) · Bronchitis, Chronic (1) · Cough (1) · Gastroesophageal Reflux (1) · Idiopathic Pulmonary Fibrosis (1) · Inflammation (1) · Respiratory Insufficiency (1) · upper airway cough syndrome (1)
Bronchial Diseases (15) · Respiratory Tract Diseases (15) · Digestive System Diseases (3) · Lung Diseases (3) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (2) · Genetic Diseases, Inborn (2) · Infant, Newborn, Diseases (2) · Pancreatic Diseases (2) · Pathologic Processes (2) · Pathological Conditions, Signs and Symptoms (2) · Respiration Disorders (2) · Bronchitis (1) · Chronic Disease (1) · Deglutition Disorders (1) · Disease Attributes (1)
Azithromycin (2) · Inhalation (2) · Carbocysteine (1) · Case-Control Studies (1) · Ciprofloxacin (1) · Mannitol (1) · Roflumilast (1) · Roxithromycin (1) · Saline Solution, Hypertonic (1) · Sodium Chloride (1)
Bayer (2) · Gilead Sciences (2) · Prince of Songkla University (2) · Syntara (2) · Ahn-Gook Pharmaceuticals Co.,Ltd (1) · Aradigm Corporation (1) · Belfast Health and Social Care Trust (1) · Neovii Biotech (1) · The Alfred (1) · The University of Queensland (1) · W.G.Boersma (1)
Australia (10) · United States (7) · United Kingdom (6) · Germany (5) · Canada (4) · Netherlands (4) · New Zealand (4) · Argentina (3) · Italy (3) · Latvia (3) · South Korea (3) · Spain (3) · Austria (2) · Belgium (2) · France (2)
Alan Barker, MD (2) · Kanung Saejiam, MS (2) · Anne Holland, PhD, BAppSc (1) · Anne O'Donnell, MD (1) · Brett Charlton (1) · Caroline H Nicolson, MPhysio (1) · Choon-Taek Lee, MD, PhD (1) · Chul-min Ahn, MD, PhD (1) · Diana Bilton, MD (1) · Greg Tino, MD (1) · Hee-Soon Chung, MD, PhD (1) · J. Stuart Elborn (1) · Joon Chang, MD, PhD (1)
PMID 25154045, PMID 28495619, PMID 22349069, PMID 23429964, PMID 23532241, PMID 25246664, PMID 29371383, PMID 29371384, PMID 30658914, PMID 32554534, PMID 34974413, PMID 35662406